← All peptides
Immune
Healing & Recovery
Research Chemical

VIP

Also known as: VIP, Vasoactive Intestinal Peptide

VIP (vasoactive intestinal peptide) is a 28-amino-acid signaling peptide with vasodilatory, anti-inflammatory, and immunoregulatory actions. It is studied intranasally in protocols for chronic inflammatory and biotoxin-related illness.

Last updated

Mechanism of Action

VIP binds the G-protein-coupled receptors VPAC1 and VPAC2, raising intracellular cyclic AMP in target cells. This drives smooth-muscle relaxation and vasodilation, particularly in the pulmonary and splanchnic circulations. VIP also exerts broad anti-inflammatory and immunoregulatory effects, shifting cytokine balance toward a regulatory phenotype and supporting mucosal and neural function. Its short circulating half-life has prompted intranasal delivery for sustained central and respiratory exposure in research settings.

Half-life
Very short, roughly 1 to 2 minutes in circulation
Administration Routes
intranasal, subcutaneous
Research Status
Research Chemical

Reported Benefits

  • Potent vasodilation and pulmonary smooth-muscle relaxation
  • Broad anti-inflammatory and immunoregulatory effects
  • Investigated in chronic inflammatory response protocols
  • May support mucosal and neural function
  • Studied for regulation of cytokine balance

Potential Side Effects

  • Flushing and lowered blood pressure
  • Headache or lightheadedness
  • Nasal irritation with intranasal use
  • Transient heart-rate changes
  • Limited long-term safety data

Common Dosing

For research use only: research protocols have referenced microgram-range intranasal administration; no validated self-dosing regimen exists. Not personal medical advice.

The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.

Contraindications

  • Hypotension or cardiovascular instability
  • Pregnancy and breastfeeding
  • Known peptide hypersensitivity
  • Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions

    2013

    View
  • Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

    2003

    View
  • Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis

    2010

    View
  • Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies

    1999

    View

VIP is broken down extremely quickly in the blood, so intranasal delivery is used in research to achieve more sustained respiratory and central exposure.

It strongly affects the vasculature and lungs through vasodilation and broadly modulates the immune system toward an anti-inflammatory, regulatory state.

PeptideChat is for educational and research purposes only. Nothing on this site constitutes medical advice. Peptides are sold as research chemicals only and are not intended for human use. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. PeptideChat is an independent educational resource — not a pharmacy, compounding, or 503A/503B outsourcing facility — and does not sell products or provide medical advice.